33 results about "Progeria" patented technology

This invention relates to the use of autologous stem/progenitor cells to restore or rejuvenate adult stem cell function in a mammal, wherein the restoration or rejuvenating extends lifespan and/or improves health of the mammal. In addition, the invention also relates to compositions containing one or more regulatory factors secreted or released from isolated mammalian stem/progenitor cells and use of such compositions to extend lifespan and/or improve health of a mammal. Also provided are methods of treating, delaying, preventing or reversing progeria or related syndromes in a mammal using isolated autologous or allogeneic stem/progenitor cells and/or regulatory factors secreted or released therefrom.

The invention discloses a genetic diagnosis kit which detects the early-aging syndromes of adults and belongs to the biotechnical field. A method which diagnoses the early-aging syndromes of the adults includes the following steps of: (1) gathering the blood, body fluid or tissue samples of individuals to be tested and extracting the DNA; (2) taking the DNA as a template and carrying out PRC reaction to PRC primers which are designed in accordance with the mutation sites of WRN genes to obtain products of the PRC reaction; (3) carrying out sequencing analysis to the obtained PRC products and comparing the obtained sample sequences with normal genetic sequences to determine whether mutation exists; and (4) judging whether the individuals to be tested have the early-aging syndromes caused by the mutation of the WRN genes according to the results. The invention has the advantages of providing the mutation of the WRN genes among the Chinese population for the first time and showing the correlation between the mutated genes and WS symptoms. The detection method is simple and low in cost, with direct and reliable results, and can be applied to the large-scale screening and diagnosis of the 2806insA mutation of WRN genes of Werner syndrome.

This invention relates to the use of autologous stem/progenitor cells to restore or rejuvenate adult stem cell function in a mammal, wherein the restoration or rejuvenating extends lifespan and/or improves health of the mammal. In addition, the invention also relates to compositions containing one or more regulatory factors secreted or released from isolated mammalian stem/progenitor cells and use of such compositions to extend lifespan and/or improve health of a mammal. Also provided are methods of treating, delaying, preventing or reversing progeria or related syndromes in a mammal using isolated autologous or allogeneic stem/progenitor cells and/or regulatory factors secreted or released therefrom.

A biochemical marker aided culture technique for culturing the short-period cotton varieties 'Zhongmiansuo No.16, 24, 27 and 36' with prematurity but no presenility includes such steps as hybridization between premature but non-presenile parents, using SOD, POD and CAT as selection markers to choose the crossed descendants beginning from F2 generation, and conventional breeding.

A chimeric protein that is a fusion construct of a series of functional domains is used to deliver a therapeutic agent to a human subject suffering from disease. In some embodiments, the chimeric protein includes a therapeutic region and a transportation region. The transportation region allows the chimeric protein to be moved across a cellular membrane of an affected cell within the subject. The therapeutic region can be effective in the treatment of, for example, muscular dystrophy, diastrophic dysplasia, malignant melanoma, porphyria, alpha-1 antitrypsin deficiency, Aicardi-Goutieres syndrome, cystic fibrosis, progeria, Marfan syndrome, tuberous sclerosis, adrenoleukodystrophy, and the like.

The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria.

The invention discloses a synthesizing method of image agent to diagnoze early senile dementia, which is synthesized by right-row technical path.

The invention discloses a method for down-regulating a zebra fish lmna gene by using morpholino and an established progeria disease model; a morpholino oligonucleotide recombinant plasmid lmna-MO aiming at the zebra fish lmna gene and a lmna-EGFP-pCS<2+> recombinant plasmid for specific instruction of the expression quantity of the lmna gene are respectively designed and constructed; the two recombinant plasmids are co-injected into zebra fish embryos by a microinjection way, and the expression quantity of green fluorescent proteins is used as a lmna expression down-regulation mark, so that the zebra fish animal model with down-regulated lmna gene expression is established. The zebra fish animal model with down-regulated lmna gene expression is established, and can provide an animal model for deep research of laminopathy.

The invention discloses a peanut senescence gene for regulating programmed cell death, a coding sequence and application. RNA (ribonucleic acid) is extracted from root tip of peanut, and is cloned to a peanut senescence gene AhSAG, and the ORF (open read frame) of the peanut senescence gene is a cDNA (complementary deoxyribonucleic acid) sequence with coding sequence of 474bp and codes of 157aa; the AhSAG comes from a peanut root tip meristematic tissue of aluminum-induced peanut root tip generating programmed cell death, and is a senescence induction enhanced gene to induce, activate and promote progeria of plants. The peanut senescence disclosed by the invention can be expressed in tobacco, and can be used for regulating the adaptability of plant cells to environment changes and maintaining environmental stability and synthesis capacity in the cell.

The invention discloses a yellow dog penis extractive with resistance to ovarian function progeria as well as a preparation method and applications thereof. The extractive is prepared by using the preparation method comprising the following steps: taking yellow dog penis slices firstly, soaking the yellow dog penis slices in ethanol with the concentration of 90-95 percent for 2-4h; then, extracting with supercritical CO2 fluid to obtain an extract; and drying in vacuum to obtain a yellow dog penis extractive, wherein the supercritical CO2 fluid is prepared under the extraction conditions: theextraction pressure is 25MPa, the extraction temperature is 65 DEG C, a separation kettle I has the pressure of 5 MPa and the temperature of 40 DEG C; a separation kettle II has the pressure of 5 MPaand the temperature of 35 DEG C; the entrainer is 95% ethanol; and the extraction time is 2h. The yellow dog penis extractive provided by the invention has high active ingredient content and less inactive large-polarity compounds and determines the optimal process with highest active ingredient extraction efficiency by inspecting the extraction pressure, the extraction temperature and the extraction time of the supercritical CO2, the entrainer and the dosage thereof. Shown by experimental results and compared with a traditional aqueous extract or an alcohol extract, the supercritical CO2 extract has better resistance to the ovarian function progeria.

The invention belongs to the technical field of cell treating, relates to a method for treating progeria or Hutchinson-Gilford progeria syndrome, in particular to a treating agent for restoring body function aging and delaying recession of organ functions and comprising GD2+ stroma cells and KDR+ hematopoietic stem cells and further relates to application, in preparation of the treating agent for treating progeria or Hutchinson-Gilford progeria syndrome or for restoring body function aging and delaying recession of the organ functions, of the combination of the GD2+ stroma cells and the KDR+ hematopoietic stem cells. It has been found that the treating agent can be effectively used for treating progeria or Hutchinson-Gilford progeria syndrome, especially for restoring body function aging and delaying recession of the organ functions.

The present invention discloses a grape seed purple sweet potato starch which consists of the following raw materials in parts by weight: 950-980 parts of fresh purple sweet potatoes, 20-25 parts of Chinese wolfberry fruits, 40-50 parts of grape seeds, 60-70 parts of red dates, 35-40 parts of honey, 6-8 parts of semen coicis, 6-8 parts of ginsengs, etc. The purple sweet potato starch is high in purity and rich in anthocyanins, does not lead to a waste of anthocyanins, and can fully utilize purple sweet potato raw materials. The added grape seeds and lycium barbarum polysaccharides can eliminate free radicals, protect skin, prevent progeria, and enhance immunity. The red dates and honey improve the taste of starch. The added extracts of semen coicis, ginsengs, pearls, ganoderma lucidum, gentiana scabra, etc. can enable the grape seed purple sweet potato starch to have certain effects of tonifying life and whitening skin.

The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria.

Use of endothelial progenitor cells in the manufacture of a medicament for rejuvenating neovascularization capacity, ameliorating aging features, preventing aging, extending lifespan, and/or treating progeria and/or age-related diseases. A method for rejuvenating neovascularization capacity, ameliorating aging features, preventing aging, extending lifespan, and/or treating progeria and/or age-related diseases, includes: administering a pharmaceutically effective amount of EPCs to a subject in need thereof.

The present invention relates to compounds of general Formula (I), and/or tautomers, enantiomers, solvates, hydrates, and pharmaceutically acceptable salts thereof. The present invention also relatesto compounds of Formula (I) for use in therapy, methods of treating isoprenylcysteine carboxyl methyltransferase (ICMT) related disorders or uses of compounds of Formula (I) in the manufacture of a medicament for the treatment of ICMT-related disorders, wherein the disorder is cancer and/or progeria. The present invention further relates to processes for synthesizing compounds of Formula (I).

The present disclosure provides compounds comprising oligonucleotides complementary to a portion of the LMNA gene. Such compounds are useful for modulating the expression of LMNA in a cell or animal, and in certain instances reducing the amount of progerin mRNA and/or progerin protein. Progerin mRNA results from aberrant splicing of LMNA and is translated to generate progerin protein. Accumulation of progerin protein causes Hutchinson-Gilford progeria syndrome (HOPS), a premature aging disease. In certain embodiments, hybridization of oligonucleotides complementary to a portion of the LMNA gene results in a decrease in the amount of progerin mRNA and/or progerin protein. In certain embodiments, oligonucleotides are used to treat Hutchinson-Gilford Progeria Syndrome.